A new era in the treatment of multiple sclerosis

Broadley, Simon A., Barnett, Michael H., Boggild, Mike, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A. L., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith M., Taylor, Bruce V., Carroll, William M., Kilpatrick, Trevor J., King, John, McCombe, Pamela A., Pollard, John D. and Willoughby, Ernest (2015) A new era in the treatment of multiple sclerosis. Medical Journal of Australia, 203 3: 139-141e.1. doi:10.5694/mja14.01218

Author Broadley, Simon A.
Barnett, Michael H.
Boggild, Mike
Brew, Bruce J.
Butzkueven, Helmut
Heard, Robert
Hodgkinson, Suzanne
Kermode, Allan G.
Lechner-Scott, Jeannette
Macdonell, Richard A. L.
Marriott, Mark
Mason, Deborah F.
Parratt, John
Reddel, Stephen W.
Shaw, Cameron P.
Slee, Mark
Spies, Judith M.
Taylor, Bruce V.
Carroll, William M.
Kilpatrick, Trevor J.
King, John
McCombe, Pamela A.
Pollard, John D.
Willoughby, Ernest
Title A new era in the treatment of multiple sclerosis
Journal name Medical Journal of Australia   Check publisher's open access policy
ISSN 1326-5377
Publication date 2015-08-03
Year available 2015
Sub-type Article (original research)
DOI 10.5694/mja14.01218
Open Access Status Not yet assessed
Volume 203
Issue 3
Start page 139
End page 141e.1
Total pages 4
Place of publication Strawberry Hills NSW, Australia
Publisher Australasian Medical Publishing
Collection year 2016
Language eng
Formatted abstract
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history.

A growing understanding of the immunopathogenesis of the condition has led to an expanding array of therapies for this previously untreatable disease.

While a cure for MS remains elusive, the potential to reduce inflammatory disease activity by preventing relapses and minimising disease progression is achievable.

The importance of early treatment in minimising long-term disability is increasingly recognised.

Most of the newer, more effective therapies are associated with risks and practical problems that necessitate an active management strategy and continuous vigilance.

While the initiation of these therapies is likely to remain the responsibility of neurologists, other specialist physicians and general practitioners will be involved in the identification and management of adverse effects.
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: UQ Centre for Clinical Research Publications
Official 2016 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 18 Aug 2015, 02:27:21 EST by System User on behalf of UQ Centre for Clinical Research